Wells Fargo & Company Apellis Pharmaceuticals, Inc. Put Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Put Options
1 transactions
Others Institutions Holding APLS
# of Institutions
301Shares Held
114MCall Options Held
5.21MPut Options Held
691K-
Wellington Management Group LLP Boston, MA16.4MShares$471 Million0.11% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.6MShares$334 Million15.74% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$319 Million5.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$282 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$167 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.16B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...